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Abstract: Metabolic complications are commonly found in people treated 
with clozapine. Reviews on the management of this problem have generally 
drawn conclusions by grouping different types of studies involving 
patients treated with various different antipsychotics. We carried out a 
systematic review and meta-analysis of pharmacological and non-
pharmacological treatments for clozapine-induced obesity or metabolic 
syndrome. Two researchers independently searched PubMed and Embase for 
randomised controlled trials (RCTs) of treatments for clozapine-induced 
obesity or metabolic syndrome. All other types of studies were excluded. 
We only included RCTs where more than 50% of participants were taking 
clozapine.   
We identified 15 RCTs. Effective pharmacological treatments for 
clozapine-induced obesity and metabolic syndrome include metformin, 
aripiprazole, and Orlistat (in men only). Meta-analysis of three studies 
showed a robust effect of metformin in reducing body mass index and waist 
circumference but no effects on blood glucose, triglyceride levels, or 
HDL levels. In addition, there is limited evidence for combined calorie 
restriction and exercise as a non-pharmacological alternative for the 
treatment of clozapine-induced obesity, but only in an in-patient 
setting. Rosiglitazone, topiramate, sibutramine, phenylpropanolamine, 
modafinil, and atomoxetine have not shown to be beneficial, despite 
reports of efficacy in other populations treated with different 
antipsychotics. 
We conclude that randomised-controlled trial data support the use of 
metformin, aripiprazole, and Orlistat (in men only) for treating 
clozapine-induced obesity. Calorie restriction in combination with an 
exercise programme may be effective as a non-pharmacological alternative. 
Findings from trials in different populations should not be extrapolated 
to people being treated with clozapine.  
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Abstract: 
Objective: To carry out a systematic review and meta-analysis of pharmacological and non-
pharmacological treatments for clozapine-induced obesity or metabolic syndrome.  
Methods: Two researchers independently searched PubMed and Embase for randomised 
controlled trials (RCTs) of treatments for clozapine-induced obesity or metabolic syndrome. 
All other types of studies were excluded. We only included RCTs where more than 50% of 
participants were taking clozapine.   
Results: We identified 15 RCTs. Effective pharmacological treatments for clozapine-induced 
obesity and metabolic syndrome include metformin, aripiprazole, and Orlistat (in men only). 
Meta-analysis of three studies showed a robust effect of metformin in reducing body mass 
index and waist circumference but no effects on blood glucose, triglyceride levels, or HDL 
levels. In addition, there is limited evidence for combined calorie restriction and exercise as a 
non-pharmacological alternative for the treatment of clozapine-induced obesity, but only in 
an in-patient setting. Rosiglitazone, topiramate, sibutramine, phenylpropanolamine, 
modafinil, and atomoxetine have not shown to be beneficial, despite reports of efficacy in 
other populations. 
Conclusion: Randomised-controlled trial data support the use of metformin, aripiprazole, and 
Orlistat (in men only) for treating clozapine-induced obesity. Calorie restriction in 
combination with an exercise programme may be effective as a non-pharmacological 
alternative. Findings from trials in different populations should not be extrapolated to people 
being treated with clozapine. Further trials focusing on clozapine-induced obesity and 
metabolic syndrome are needed. 
Keywords: schizophrenia, clozapine, metabolic syndrome, treatment, meta-analysis  
Abbreviations: BMI: Body mass index; CHAOS: Coronary artery disease, hypertension, 
atherosclerosis, obesity, and stroke; HbA1c: Glycosylated haemoglobin; HDL: High-density 
lipoprotein; Kg: kilogram; LDL: Low-density lipoprotein; RCT: Randomised controlled trial; 
VLDL: Very-low-density lipoprotein. 
 
1 Introduction 
Average life expectancy in people with schizophrenia is about 20 years shorter than the 
general population – this difference is largely attributed to increased mortality from chronic 
physical conditions such as heart disease and diabetes mellitus (Saha et al., 2007). 
Cardiometabolic complications such as weight gain, obesity, metabolic syndrome and 
diabetes mellitus are well recognized side effects of antipsychotics particularly the atypicals 
which are widely used today (De Hert et al., 2011).  
Clozapine is generally regarded as the most efficacious antipsychotic drug (Leucht et al., 
2013), but has been associated with the highest risk for developing obesity and metabolic 
complications compared with other atypical antipsychotics (Allison et al., 1999; Bodén et al., 
2013; Gianfrancesco et al., 2002). It is estimated that the prevalence of metabolic syndrome 
in long-term clozapine users ranges from 28 to 45% (Bai et al., 2011; Bodén et al., 2013).  
Clozapine has affinities for many receptors from multiple neurotransmitter systems. These 
include the dopamine (D1 – D5), serotonin (5-HT1A/1D, 5-HT2A/2C, 5-HT3, 5-HT6, and 5-
HT7), histaminergic (H1 – H3), muscarinic (M1 – 5), adrenergic (α1-2 and β1-3), and 
GABAA receptors (Meltzer, 1994). The difference in the receptor binding profiles of 
different antipsychotics is thought to account for the different weight gain liabilities 
associated with them (Reynolds and Kirk, 2010). The weight gain induced by clozapine is 
highly variable and a twin study by Theisen and colleagues has shown that it is more highly 
correlated in monozygotic twins than in siblings, suggesting that genetic factors may play a 
major role (Theisen et al., 2005). More than 200 genes or markers have been linked to human 
obesity and many of them could be important in clozapine-induced obesity (Basile et al., 
2001).  
 
It has been hypothesised that clozapine causes obesity via its actions on the serotonergic and 
histaminergic systems. Rat studies have shown that 5-HT1A agonists and 5-HT2C/2A 
antagonists cause a marked increase in feeding (Yamada et al., 1996). Clozapine is a potent 
5-HT2C/2A antagonist and a 5-HT1A partial agonist. H1 antagonism is known to be 
associated with increased feeding and weight gain, and antipsychotics with a high propensity 
for weight gain, like clozapine, have strong affinities for the H1 receptor (Wirshing et al., 
1999). Two meta-analyses (De Luca et al., 2007; Sicard et al., 2010) have linked 
polymorphisms in the serotonergic system to clozapine-induced obesity, making it the most 
robust pharmacogenetic mechanism to date that could explain some of the variation in weight 
gain amongst these patients. Despite the evidence, it must be noted that some studies have not 
found such association(Basile et al., 2001; Rietschel et al., 1997; Yevtushenko et al., 2007). 
Results in studies looking at the histaminergic system have shown positive (Vehof et al., 
2011) and negative (Hong et al., 2002) findings. Reviews of the literature (Basile et al., 2001; 
Lett et al., 2012; Müller et al., 2004; Reynolds, 2012) highlight many other targets that have 
been investigated in order to try to explain the variation in weight gain seen in people taking 
clozapine. The results of this research provide clues to the mechanisms behind clozapine-
induced weight gain, but our understanding of this complex phenomenon is still limited and 
further research is warranted. 
Clozapine is the gold standard for managing treatment-resistant schizophrenia, which 
comprises approximately 25% of all patients with this condition (Brenner et al., 1990). 
Clozapine is the only antipsychotic approved by the US Food and Drug Administration 
(FDA) for treatment-resistant schizophrenia (Novartis, 2002). Similarly, the UK national 
institute for health and care excellence (NICE) recommends clozapine as the treatment of 
choice for patients who do not respond to two antipsychotics (NICE, 2014). Clinicians, 
therefore, are faced with a difficult choice between efficacy and long-term cardiometabolic 
complications when choosing clozapine. 
We present a systematic review and meta-analysis of pharmacological and non-
pharmacological treatments for clozapine-induced obesity and metabolic syndrome. Previous 
reviews have considered the effect of weight loss treatments for patients who take 
antipsychotics (Faulkner et al., 2007, 2003; Maayan et al., 2010), but these have included 
studies of various different antipsychotics. Different antipsychotics have very different 
effects on weight gain and metabolic risk (Leucht et al., 2013), so there is a need to focus on 
particular antipsychotics in order to reduce heterogeneity. Given the different mechanisms of 
action of different antipsychotics, and their different metabolic effects, it is reasonable to 
suggest that treatments that may work with one antipsychotic, may not work with another. 
Whitney and colleagues have focused on clozapine (Whitney et al., 2015), but the review 
presented here is distinct in two ways. We report an up-to-date, systematic review and a 
meta-analysis (for metformin) of randomised controlled trials (RCTs) of pharmacological and 
other treatments for clozapine induced obesity and metabolic syndrome. 
2 METHODS 
2.1 Search Strategy 
The PubMed and Embase electronic databases were searched from their inception until the 
30
th
 July, 2015 for all studies (without any filters) involving the management of obesity or 
metabolic syndrome in people taking clozapine using the following search terms: (clozapine 
OR norclozapine OR clozaril OR gen-clozapine OR analeptic OR leponex OR fazaclo OR 
froidir OR denzapine OR zaponex OR klozapol OR clopine) AND (obesity OR (weight AND 
gain) OR (high AND BMI) OR overweight OR obese OR (metabolic AND syndrome) OR 
(syndrome AND X) OR (cardiometabolic AND syndrome) OR (Reaven's AND syndrome) 
OR CHAOS) AND (treatment OR programme OR management OR manage OR managing 
OR therapy OR diet OR regimen OR intervention OR trial OR (randomised AND 
controlled)). An automated search alerted the authors (JZ & CT) by email with any new 
articles published matching the search terms, which was in use up until December 2015. No 
further suitable articles were identified in this way. Reference lists of included studies and 
relevant review articles were hand searched. Two studies were added from this process (Fan 
et al., 2013; Henderson et al., 2011). 
2.2 Study selection 
Double-blind RCTs of interventions to address clozapine-induced obesity or metabolic 
syndrome were selected. Additionally, RCTs where blinding was not possible due to the 
nature of the treatment involved were also included. Studies where some participants were on 
other antipsychotics were included, provided that clozapine was prescribed to the majority 
(>50%) of the study participants and that separate analyses by antipsychotic type were 
conducted. Case reports, case series, and non-randomised trials were excluded. 
2.3 Data extraction 
Two researchers (JZ, CT) carried out the literature search, examined search results, applied 
selection criteria, and selected suitable articles independently by going through all titles and 
abstracts. A list was compiled after discussing potential articles for the review and the full 
text for each article was obtained. Any exclusion after this point was discussed on a case-by-
case basis.  
2.4 Quality assessment of selected studies: 
All the studies included in this review were assessed for quality using the “Consolidated 
Standards of Reporting Trials (CONSORT) statement” checklist (Schulz et al., 2010). There 
are 25 items on the checklist, but some are subdivided into further items, giving a total 
maximum of 37 standards (not all of which are applicable to every study). We calculated a 
quality score for each study, which is the percentage of total applicable standards met by each 
study.  
2.5 Data Synthesis for Meta-Analysis 
Quantitative meta-analysis combined the outcomes of body mass index (BMI), waist 
circumference, serum glucose, high density lipoprotein (HDL) cholesterol, and triglycerides 
from three available trials of metformin as the active treatment (Carrizo et al., 2009; Chen et 
al., 2013; Hebrani et al., 2015). For each outcome, first we calculated mean change-from-
baseline and its standard deviation (SD) for metformin and placebo groups at the end of 
follow-up. Then we calculated mean difference and 95% confidence intervals of mean 
change-from-baseline between groups, which were combined using fixed effect meta-
analysis. Studies were weighted using inverse variance method. Heterogeneity between study 
samples was assessed using Chi-squared test. The I
2
 statistic was calculated to express the 
fraction of variation between studies that was due to heterogeneity (Higgins et al., 2003). 
Because the length of follow-up varied between trials, we used measurements that were taken 
sufficiently close to each other between studies (Carrizo et al at 14 weeks; Chen et al and 
Hebrani et al at 16 weeks). When SD for mean change-from-baseline was not reported we 
used the values for the same outcome measure from other studies in the review. This 
approach is appropriate because the methods for measuring the main outcomes (BMI and 
waist circumference) were similar between studies, and so was the duration of follow-up. 
Meta-analysis was carried out using the software RevMan, version 5.3, freely available from 
the Cochrane collaboration database (Cochrane Informatics & Knowledge Management 
Department, 2015). 
3 RESULTS 
Figure 1 summarises the study selection process for this systematic review. The electronic 
database search yielded 2,370 articles. Twelve other articles were identified from a manual 
search. Screening of titles and abstracts identified 44 potentially suitable articles for the 
review, of which 29 were subsequently discarded after examination of full text versions (see 
online supplementary table for excluded studies).  
[figure 1 here] 
Fifteen studies met the selection criteria. These can be broadly divided into research looking 
at pharmacological, non-pharmacological, and combination of both pharmacological and 
non-pharmacological treatments. The key interventions and findings of these studies are 
summarised in Table 1. 
3.1 Pharmacological Treatments 
3.1.1 Meta-analysis of RCTs of Metformin 
Three RCTs examined metformin as a sole treatment for clozapine-induced obesity and 
metabolic syndrome (Carrizo et al., 2009; Chen et al., 2013; Hebrani et al., 2015). These 
studies carried out a completer analysis of the data. Chen and colleagues did not report any 
participants failing to complete the study (Chen et al., 2013). Carrizo and colleagues reported 
that 7 participants (23%) in the treatment group did not complete the trial (Carrizo et al., 
2009). Hebrani and colleagues had a large drop-out rate with 11 participants (37%) stopping 
the intervention, although 12 participants (40%) in the placebo group also failed to complete 
the study (Hebrani et al., 2015). 
Metformin is an effective and widely used treatment for diabetes mellitus. It is a biguanide 
with antihyperglycaemic effects and is the most studied pharmacological agent for treating 
obesity and metabolic syndrome caused by antipsychotics in general (Fiedorowicz et al., 
2012).  It lowers both basal and postprandial plasma glucose, but it does not stimulate insulin 
secretion and, hence, does not produce hypoglycaemia.  
3.1.1.1 Effect on BMI and Waist Circumference 
Data on BMI and waist circumference were available from all three RCTs, totalling 71 
participants in the metformin group and 75 participants in the placebo group. Metformin 
treatment was associated significant reductions in BMI and waist circumference (Figure 2, 
panels A & B). At the end of follow-up average BMI was about 1-point lower in the 
metformin group compared with the placebo group; mean difference -0.89 (95% CI, -1.20, -
0.58); P<0.0001. There was no evidence for significant heterogeneity between studies 
(P=0.42; I
2
=0%). Similarly, at the end of follow-up average waist circumference was about 
2cms lower in the metformin group compared with the placebo group; mean difference -1.69 
(95% CI, -2.84, -0.54); P=0.004. Again, no evidence for significant heterogeneity was found 
between studies (P=0.57; I
2
=0%). 
[Figure 2, Panels A-B] 
3.1.1.2  Effect on Blood Glucose and Lipids  
No significant difference between metformin and placebo groups was observed for blood 
glucose, HDL cholesterol and triglyceride levels (Figure 2, panels C-E). 
[Figure 2, Panels C-E] 
3.1.2 Rosiglitazone 
Rosiglitazone is used in monotherapy or combination therapy in patients with diabetes 
mellitus. It works at the transcription factor level in cells that metabolise glucose and fat, with 
the net effect of lowering fasting and post-prandial blood glucose levels and HbA1c levels, 
without causing hypoglycaemia (Yki-Järvinen, 2004). Henderson and colleagues (Henderson 
et al., 2009) looked at the effect of rosiglitazone in a small group of participants (n=18) who 
were treated for 8 weeks. They found no difference in weight, BMI, waist circumference, 
waist-hip ratio, or body fat percentage between groups, but there was some evidence of a 
reduction in low-density lipoprotein (LDL) (effect size = 0.30; p = 0.04) in the treatment 
group. 
3.1.3 Modafinil 
Henderson and colleagues (Henderson et al., 2011) conducted a secondary analysis of a study 
(Freudenreich et al., 2009) looking at the effect of modafinil treatment for 8 weeks on weight 
gain, glucose, lipid metabolism, and diet. They found no significant differences between 
groups in terms of blood pressure, weight, BMI, glucose, insulin resistance, or lipid 
metabolism at the end of follow up. 
3.1.4 Orlistat 
Orlistat, a lipase inhibitor that reduces fat absorption from the intestines (Lucas and Kaplan-
Machlis, 2001), is the only pharmacological treatment available that is not absorbed into the 
central nervous system.  
Joffe and colleagues (Joffe et al., 2008) conducted a RCT looking at the effects of Orlistat on 
weight, fasting glucose, and blood lipids in a group of 63 patients being treated with 
clozapine (n = 50 [79%]) or olanzapine (n = 13 [11%]). The drop-out rates in this study were 
considerable with 7 patients in the treatment group (23%) and 7 in the placebo group (22%) 
failing to complete the study, but the researchers used intention-to-treat analyses to interpret 
the data. After 16 weeks, the only difference they found was a 2.3kg mean weight loss in men 
treated with Orlistat, but not in women. Five people (16.1%) were classified as ‘responders’ 
(>5% weight loss) in the treatment group vs. 2 (6.3%) in the placebo group, but the 
differences were not statistically significant (Fisher exact test, p = 0.26). The amount of 
weight loss seen is similar to that in trials of Orlistat in the non-psychiatric population 
(Padwal et al., 2004). Diarrhoea was the main reason for discontinuation of Orlistat (4 
patients). In a subsequent publication of the same trial (Tchoukhine et al., 2011), they 
analysed the effects of administering Orlistat for a further 16 weeks to participants who 
completed the initial trial, but no additional benefit was found. 
3.1.5 Topiramate 
We found three trials looking at the effects on psychotic symptoms of adding the 
anticonvulsant topiramate to clozapine treatment (Afshar et al., 2009; Behdani et al., 2011; 
Muscatello et al., 2011). Weight loss was not the primary outcome and was simply 
highlighted as a side effect, hence only limited data is available and meta-analysis was not 
possible. Afshar and colleagues (Afshar et al., 2009) conducted an 8 week, double-blind, 
placebo controlled, randomised trial (n=32) where there was no effect of topiramate 
(300mg/day) on BMI observed. A significantly greater proportion of people in the topiramate 
group reported “weight loss” when compared with those given placebo (37.5% vs. 6.2% [p ≤ 
0.05]), although the amount of weight loss was not defined. No further information is 
available from the study. 
The study of Muscatello and colleagues (Muscatello et al., 2011) mentions a 1kg difference 
in the topiramate group (200mg/day) after 24 weeks of treatment. The weight difference in 
the placebo group is not reported and the weight loss observed was not found to be 
statistically significant (p = 0.236). 
Finally, Behdani and colleagues (Behdani et al., 2011) conducted a 17 week trial of 
augmenting clozapine with topiramate (200 - 300mg/day). They report that 15% (n= 6) of the 
topiramate group experienced 'weight loss' in comparison with 0% of the placebo group. 
Statistical analyses were not carried out and 'weight loss' is not defined. 
3.1.6 Sibutramine 
Sibutramine was introduced to the US in 1997 as a weight loss agent. It affects serotonin and 
noradrenaline re-uptake, and its hypophagic effect is thought to be mediated by activation of 
the 5-HT2C receptor. It has been withdrawn following evidence that it increases the risk of 
cardiovascular complications (European Medicines Agency, 2010). Following a trial showing 
sibutramine is effective for weight loss in olanzapine treated patients (Henderson et al., 
2005), Henderson and colleagues carried out a 12 week, double-blind, placebo-controlled, 
randomised trial in 21 patients on clozapine (Henderson et al., 2007). They looked at changes 
from baseline in body weight, BMI, waist circumference, glucose, HbA1c, blood lipids, 
Positive and Negative Syndrome Scale (PANSS) scores, blood pressure, and heart rate, but 
found no significant difference on any these measures between groups. 
3.1.7 Phenylpropanolamine 
Phenylpropanolamine is an α1-agonist thought to act as an appetite suppressant by 
augmenting noradrenergic neurotransmission, which used to be sold over-the-counter as a 
treatment for obesity until it was discovered that it increases the risk of haemorrhagic stroke 
in women (Kernan et al., 2000). Borovicka and colleagues (Borovicka et al., 2002) carried 
out the only double-blind, RCT with this agent in 16 people taking clozapine. After 12 weeks, 
no difference was found between the treatment and the placebo group in terms of weight, 
glucose, HbA1c, or cholesterol levels. 
3.1.8 Aripiprazole 
We identified two studies of Aripiprazole, which were not meta-analysed due to differences 
in methods and duration of follow up. Fleischhacker and colleagues conducted a large, multi-
centre study (n=207), to evaluate the effects of adding aripiprazole to clozapine 
(Fleischhacker et al., 2010). In a last observation carried forward analysis, they found that 
aripiprazole reduced weight (mean treatment difference of -2.15 kg), BMI (-0.8 kg/m
2
), LDL 
cholesterol (-10.3 mg/dL), and waist circumference (-2.0 cm) after a treatment period of 16 
weeks. There was no difference in PANSS scores between the treatment group and controls, 
but there were some improvements in the Clinical Global Impression (CGI) scale and in the 
Impressions and Investigator’s Assessment questionnaire in the treatment group. In the 
placebo group 6 (6%) patients failed to complete the study and there were 11 (10%) drop-
outs in those receiving aripiprazole, with 5 (5%) due to adverse events. Some of their results 
are supported by a more recent trial (n = 30) by Fan and colleagues (Fan et al., 2013). They 
looked at the effects of adding 15mg of aripiprazole to patients on clozapine for a period of 8 
weeks. The treatment group showed significant reductions in plasma LDL levels, improved 
glucose effectiveness as measured by the frequently sampled intravenous glucose tolerance 
test, as well as a significant reduction in lean mass (-1.1 ± 1.6kg vs 0.6 ± 1.6kg in placebo) as 
measured by whole-body dual-energy X-ray absorptiometry. There were similar proportions 
of drop-outs in both arms of the study (4 in the placebo (22%) and 4 (20%) in the treatment 
group). It is not specified whether some of their data was used in the analysis or not. 
3.2 Non-Pharmacological treatments 
3.2.1 Calorie restriction and exercise 
Wu and colleagues (Wu et al., 2007) carried out a 6 month RCT of exercise and calorie 
restriction versus treatment as usual in 53 inpatients with schizophrenia taking clozapine. The 
exercise component was designed to fit the hospital environment, and it consisted of three 
days per week of level walking (1.62km or ~40 minutes) together with walking up 231 stairs 
and down 330 stairs for 20 minutes under supervision (exercise energy expenditure per week 
= 600 – 750kcal). Dietary control consisted of 1300 – 1500kcal/day for women and 1600-
1800kcal/day for men. The treatment group had reductions in BMI (- 1.59kg/m2), body 
weight (-4.2kg), hip (-3.3cm) and waist circumference (-3.3cm) after 6 months. They also had 
lower levels of triglycerides, insulin, and cortisol. No group differences were found in 
glucose and cholesterol levels. There were no drop-outs in the treatment group and only 3 
(11%) in the control group. 
3.3 Combination treatments 
3.3.1 Atomoxetine and Weight Watcher’s Programme 
Atomoxetine is a selective norepinephrine reuptake inhibitor used in attention deficit 
hyperactivity disorder, which has been found to have appetite suppressant properties (Spencer 
et al., 1998). It has been postulated to improve cognitive impairments in schizophrenia, 
although scientific evidence for this idea is lacking (Friedman et al., 2008). In a 24 week 
double-blind randomised controlled trial (n=37), Ball and colleagues (Ball et al., 2011) tested 
whether atomoxetine could help achieve weight loss in clozapine (52% of sample) and 
olanzapine treated patients. All participants also undertook a 10 week ‘Weight Watchers’ 
programme (a weight loss programme mainly used in the US, UK, Ireland and Australia) 
which involved diet and exercise. No significant differences were found with regards to 
weight loss, LDL, HDL, triglycerides, very-low-density lipoprotein (VLDL), cognitive 
measures, or symptomatology between groups. Of interest, only 9 (24%) participants (6 on 
placebo and 3 on atomoxetine) who completed the study were adherent to the exercise 
programme, but the amount of weight loss they experienced ranged from <3% to 14% of 
their study baseline weight. 
[Table 1 about here] 
4 Discussion 
Few RCTs looking at treatments for obesity and metabolic syndrome caused by clozapine are 
available. Our results suggest that adjuvant treatment with metformin, aripiprazole or Orlistat 
might be effective pharmacological strategies, albeit with limited clinical impact.  
The evidence on metformin in clozapine-treated patients suggests that its use is likely to have 
a small beneficial effect with regards to body weight, blood lipids, and insulin levels. This is 
thought to be caused by its effects in enhancing the glycaemic control effects of insulin, 
antagonising glucagon, and suppressing gluconeogenesis and glycogenolysis (Wiernsperger 
and Bailey, 1999). Given the short duration of the follow-ups (6 months or less), it is not 
clear as to whether these changes eventually translate to clinically significant effects. One of 
the problems is that benefits seem to stop once metformin is withdrawn (Chen et al., 2013), 
therefore, treatment is likely to be required for life. Adverse effects can also occur and these 
resulted in 6 (20%) of the participants from one study discontinuing the drug (Hebrani et al., 
2015). Metformin is also contraindicated in patients with ketosis-prone diabetes and 
underlying renal, hepatic, or cardiopulmonary disease (Wang et al., 2012). 
Aripiprazole appears to be the only other agent with good evidence against obesity and 
metabolic syndrome induced by clozapine (Fan et al., 2013; Fleischhacker et al., 2010). Its 
effects on weight and cholesterol reduction are thought to be due to its partial agonist effects 
on 5-HT1A receptors and agonist effects on 5-HT2C receptors (Fan et al., 2013). Potential 
candidates need to be warned about the possibility of side effects, such as akathisia, which 
were observed in some study participants and accounted for nearly half of the drop-outs. It is 
still unclear whether any benefits continue after 7 months. 
The results on rosiglitazone (Henderson et al., 2009), topiramate (Afshar et al., 2009), 
modafinil (Henderson et al., 2011), sibutramine (Henderson et al., 2007), 
phenylpropanolamine (Borovicka et al., 2002), and atomoxetine (Ball et al., 2011) are 
disappointing. The effects of Orlistat in body weight appear to be small, limited to men, with 
no further benefit after 16 weeks of use. Some participants also developed diarrhoea, which 
led to discontinuation of the treatment (Joffe et al., 2008). Some studies argue that the lack of 
effect in these agents may be due to a small sample size; however, even if larger samples 
managed to show statistical significance, the magnitude of the effects of these drugs in body 
weight and features of metabolic syndrome would still be small and unlikely to be of much 
clinical significance. 
The effects of calorie restriction and exercise appear to be at least as good, if not better, than 
those of metformin and aripiprazole (Ball et al., 2011; Wu et al., 2007). The study by Wu and 
colleagues produced the best results, but the Chinese participants were all long-term 
inpatients under close scrutiny. They achieved a 90% completion rate in their six-month 
exercise programme without any significant incentives. In the UK, the median length of 
admission is 15 days and only 9.2% of patients are admitted for longer than 90 days 
(Thompson et al., 2004). Achieving that level of commitment in the community would be 
difficult, as can be seen in the US-based study by Ball and colleagues, where only 9 (24%) of 
participants completed the exercise programme, despite provision of free transport to the 
exercise sessions and incentives in the form of tokens that could be used to buy prizes at the 
end of the study. Nevertheless, every participant that finished the programme lost a 
substantial (~3 – 15.9kg) amount of weight (Ball et al., 2011).  
This review shows that treatments that have been successful in ‘atypical’ antipsychotics can 
fail when tested in people taking clozapine. Positive weight loss trials with topiramate in 
people taking atypical antipsychotics (Ko et al., 2005) were not replicated in people treated 
with clozapine (Afshar et al., 2009). A positive trial of sibutramine in people taking 
olanzapine (Henderson et al., 2005) did not translate to clozapine (Henderson et al., 2007).  A 
trial suggestive of modafinil having an impact in cholesterol levels of people treated with 
‘atypical antipsychotics’ (Sudhakar et al., 2008) was not replicated in clozapine-treated 
patients (Henderson et al., 2011). The same applies for medication found to be helpful in the 
general population, as can be seen in the failure of phenylpropanolamine (Borovicka et al., 
2002) and sibutramine (Henderson et al., 2007) in clozapine patients. The lack of an effect of 
these agents on clozapine-treated individuals may be due to different weight gain 
mechanisms given the different receptor affinities of clozapine. 
Limiting the inclusion criteria of this review to randomised controlled trials favoured the 
inclusion of a small number of studies with a low risk of bias over a greater number of studies 
that would have been available, had other types of studies been considered. Given that 
clozapine has been continuously used for over 25 years, it was expected that a larger number 
of randomised controlled trials would have been carried out, but, unfortunately, this was not 
the case. The exclusion of all other types of evidence such as case reports and observational 
studies was done to try to eliminate bias. The limited information available on the topic, 
however, means that useful information may still be obtained from lower levels of evidence 
and the reader should consider looking at those studies that were excluded, as well as looking 
at more general reviews (Faulkner et al., 2007, 2003; Maayan et al., 2010; Whitney et al., 
2015), in order to obtain a broader view of the evidence. 
We conclude that there is evidence for pharmacological and non-pharmacological 
interventions that can help with the metabolic complications of clozapine treatment. The 
benefits of pharmacological interventions have to be weighed against potential side-effects 
and non-pharmacological alternatives can be effective but difficult to implement in 
community settings. The limited impact of all these interventions on clozapine-induced 
metabolic syndrome highlights the need for further research in this field. 
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Figure legend 
 
Figure 1. Study flow diagram for systematic review. PubMed and Embase were searched 
from their inception until 1st December, 2015. The key search terms used included 
'randomised controlled trial', intervention, treatment, BMI, obesity, metabolic syndrome, and 
generic and proprietary terms for clozapine (see Methods).  
Figure 2. 
A: Meta-analysis of metformin on BMI. 
B: Meta-analysis of metformin on waist circumference. 
C: Meta-analysis of metformin on fasting blood glucose levels. 
D: Meta-analysis of metformin on HDL cholesterol levels. 
E Meta-analysis of metformin on triglyceride levels. 
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T Score* 
 
Pharmacological Studies  
Carrizo 
(2009) 
Venezue
la 
Metformin 
500mg/day for 2 
weeks, then 
1000mg/day 
61 100% Out-patients 
14 
weeks 
-1.87kg 
metformin 
vs. +0.16kg 
in placebo. 
N/A 
Increased 
HDL in 
treatment 
group. 
Reduced 
insulin 
levels in 
treatment 
group. 
No 
significan
t changes 
in BPRS 
scores. 
75% 
Chen (2013) China 
Metformin 
1500mg/day 
55 100% 
Out-
patients. 
BMI >24 or 
metabolic 
abnormalitie
s 
24 
weeks 
on 
treatme
nt + 24 
weeks 
without. 
-3.2kg at 24 
weeks 
(effect lost 
when 
metformin 
stopped). 
-1.2 at 24 
weeks 
(effect 
lost when 
metformin 
stopped) 
Reduction 
in 
triglyceride
s in 
metformin 
group. 
Reduced 
fasting 
glucose in 
treatment 
group. 
No 
significan
t changes 
in 
PANSS 
scores. 
80% 
Hebrani 
(2015) 
Iran 
Metformin 
500mg/day for 1 
week, then 
1000mg/day 
37 100% 
In-patients 
with a BMI 
>25 
16 
weeks 
on 
treatme
nt + 4 
weeks 
without. 
- 1.7cm 
waist 
circumferenc
e metformin 
vs. +1.0cm 
placebo. 
-1.23 
metformin 
vs. +0.01 
placebo. 
Reduced 
HDL 
No 
difference
s in 
fasting 
glucose 
levels. 
No 
significan
t changes 
in BPRS 
scores. 
69% 
Henderson 
(2009) 
USA 
Rosiglitazone 
4mg/day 
18 100% 
Out-patients 
Insulin 
resistance or 
impaired 
glucose 
metabolism. 
8 weeks 
No 
significant 
difference in 
weight, 
weight 
circumferenc
e or waist-
hip ratio. 
No 
significant 
difference
s 
Reduced 
small LDL 
particle in 
treatment 
group. 
No 
significant 
changes. 
No 
significan
t changes 
in 
PANSS 
scores. 
53% 
Joffe (2008) Finland Orlistat 360mg/day 63 79% 
90% 
inpatients, 
10% 
outpatients 
receiving 
clozapine or 
olanzapine. 
BMI 28 - 
43. 
16 
weeks 
-2.36 kg 
Orlistat vs. 
+0.62kg 
placebo in 
men. 
Women did 
not benefit. 
N/A 
Reduced 
LDL in 
placebo. 
No 
significant 
changes. 
N/A 69% 
Afshar 
(2009) 
Iran 
Topiramate 
300mg/day with 
25mg increments 
as required every 4 
days 
32 100% Out-patients 8 weeks 
Weight loss 
in 37.5% 
topiramate 
vs. 6.2% 
placebo. 
Exact figures 
N/A. 
-0.91 
topiramat
e +0.21 
placebo 
N/A N/A 
Reductio
n in all 3 
categorie
s of the 
PANSS 
in 
topiramat
e group. 
64% 
Behdani 
(2011) 
Iran 
Topiramate (200 – 
300mg/day) 
80 100% In-patients 
17 
weeks 
Weight loss 
in 15% 
topiramate 
vs. 0% 
placebo. 
N/A N/A N/A 
No 
significan
t changes 
in 
PANSS 
scores. 
63% 
Muscatello 
(2011) 
Italy 
Topiramate 
(200mg/day)  
60 100% Out-patients 
24 
weeks 
-1.0 kg in 
topiramate 
group 
(placebo not 
reported) 
N/A N/A N/A 
No 
differenc
es in 
BPRS. 
Bizarre 
behaviou
r 
reduction 
in 
topiramat
e group 
63% 
Henderson 
(2011) 
USA 
Modafinil 
300mg/day 
35 100% Out-patients 8 weeks 
No 
significant 
differences 
in weight 
No 
significant 
difference
s 
No 
significant 
differences 
No 
significant 
difference
s in 
glucose 
levels or 
insulin 
resistance 
No 
significan
t 
differenc
es in 
negative 
symptom
s or 
cognition 
64% 
Henderson 
(2007) 
USA 
Sibutramine 
5-15mg/day 
21 100% 
Out-
patients. 
BMI >30 or 
>27 with 
cardiovascul
ar risk 
factors. 
12 
weeks 
No 
significant 
differences 
in weight or 
waist 
circumferenc
e. 
No 
significant 
difference
s 
No 
significant 
changes. 
No 
significant 
changes. 
No 
significan
t changes 
in 
PANSS 
scores. 
59% 
Borovicka 
(2002) 
USA 
Phenylpropanolam
ine 75mg/day 
16 100% 
Out-
patients. 
Gained 
>10% of 
baseline 
body weight 
12 
weeks 
No 
significant 
differences 
in weight 
N/A 
No 
significant 
changes. 
No 
significant 
changes. 
 
No 
significan
t changes 
in 
PANSS 
scores. 
 
55% 
Fleischhack
er (2010) 
Multi-
centre 
(10 
Europea
n 
countries 
and 
South 
Africa) 
Aripiprazole 
5-15mg/day 
20
7 
100% 
Out-
patients. 
>2.5kg 
weight gain. 
16 
weeks + 
12 
weeks 
open-
label 
extensio
n 
-2.53kg 
aripiprazole 
vs. -0.38kg 
placebo. -
2cm waist 
circumferenc
e 
aripiprazole 
vs. 0cm 
placebo. 
-0.8 
aripiprazo
le vs. 0.0 
placebo. 
 
Reduced 
LDL and 
cholesterol 
in 
treatment 
group. 
No 
difference 
in 
triglyceride
s or HDL 
levels. 
 
No 
significant 
changes. 
No 
significan
t changes 
in 
PANSS 
scores. 
81% 
Fan (2013) USA 
Aripiprazole 
15mg/day 
30 100% Out-patients 8 weeks 
 
No 
difference in 
weight or 
waist 
circumferenc
e. Reduced 
lean mass in 
treatment 
group 
-1.1 ± 1.6kg 
aripiprazole 
vs 0.6 ± 
1.6kg in 
placebo. 
 
No 
significant 
difference
s 
Reduced 
LDL 
plasma 
levels and 
LDL 
particle 
numbers in 
treatment 
group. No 
differences 
in 
cholesterol, 
HDL, or 
triglyceride
s. 
Increased 
insulin-
independe
nt glucose 
clearance 
rate in 
treatment 
group. 
No 
significan
t change 
in 
PANSS 
scores. 
64% 
Non-Pharmacological Studies  
Wu (2007) China 
Calorie restriction 
(1300-
1500kcal/day for 
women and 1600-
1800 kcal/day for 
men) and exercise 
3 times per week 
(600-750kcal of 
exercise per week) 
53 100% 
In-patients. 
BMI > 27. 
6 
months 
-4.2kg 
treatment 
group vs. 
+1kg 
controls. 
-3.3cm hip 
and -3.3cm 
waist 
circumferenc
e treatment 
group vs. 
+0.3cm & 
+0.01cm 
controls. 
-1.59 
treatment 
group vs. 
+0.35 
controls 
Reduced 
triglyceride
s in 
treatment 
group. 
Reduced 
insulin 
levels in 
treatment 
group. 
N/A 58% 
Combination Studies  
Ball (2011) USA 
Atomoxetine 40-
120mg/day + 10 
week Weight 
Watchers 
Programme vs. 
Weight Watchers 
Programme alone. 
37 52% 
Gained 7% 
or more of 
baseline 
body 
weight. 
24 
weeks 
No 
significant 
differences 
in weight. 
 
No 
significant 
changes. 
No 
significant 
changes. 
No 
significan
t changes 
in BPRS 
scores. 
62% 
 
 
Table 1. Randomised controlled trials for obesity and metabolic syndrome in patients treated with clozapine. *The CONSORT score reflects the 
proportion of applicable standards according to the CONSORT checklist (Schulz et al., 2010). Higher scores reflect higher quality of trial reporting. 
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Supplementary Table 
Studies excluded from the systematic review 
Study reference Reason for exclusion 
Henderson et al., 2005b; Kaye, 2003; Lin et al., 
2005; Masopust et al., 2008; Ozenoglu et al., 
2007; Pavlovic, 2005; Pigato et al., 2009; 
Schaefer et al., 2007; Weaver et al., 2010 
Only provided data from case reports 
Aquila and Emanuel, 2000; Cole et al., 2010; 
Hinze-Selch et al., 2000; Kalarchian et al., 2005; 
Kelly et al., 2006; Li et al., 2013; Reinstein et al., 
1999; Schorr et al., 2008 
Not randomised controlled trials 
Daumit et al., 2013; Ghanizadeh et al., 2013; 
Khazaal et al., 2007; Ko et al., 2005; Wang et al., 
2012; Wu et al., 2008 
Patient populations taking multiple 
antipsychotics and the proportion of those 
taking clozapine was less than 50% 
Fernández et al., 2012; Tchoukhine et al., 2011 
Data was obtained from studies already included 
in this review 
Chukhin et al., 2013; Fernández et al., 2010 
Did not provide useful data on weight or 
metabolic abnormalities 
Lu et al., 2004 Not blinded 
Englisch and Zink, 2008 Review article 
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Abstract: 
Objective: To carry out a systematic review and meta-analysis of pharmacological and non-
pharmacological treatments for clozapine-induced obesity or metabolic syndrome.  
Methods: Two researchers independently searched PubMed and Embase for randomised 
controlled trials (RCTs) of treatments for clozapine-induced obesity or metabolic syndrome. 
All other types of studies were excluded. We only included RCTs where more than 50% of 
participants were taking clozapine.   
Results: We identified 153 RCTs. Effective pharmacological treatments for clozapine-
induced obesity and metabolic syndrome include metformin, aripiprazole, and Orlistat (in 
men only). Meta-analysis of three studies showed a robust effect of metformin in reducing 
body mass index and waist circumference but no effects on blood glucose, triglyceride levels, 
or HDL levels. In addition, there is limited evidence for combined calorie restriction and 
exercise as a non-pharmacological alternative for the treatment of clozapine-induced obesity, 
but only in an in-patient setting. Rosiglitazone, topiramate, sibutramine, 
phenylpropanolamine, modafinil, and atomoxetine have not shown to be beneficial, despite 
reports of efficacy in other populations. 
Conclusion: Randomised-controlled trial data support the use of metformin, aripiprazole, and 
Orlistat (in men only) for treating clozapine-induced obesity. Calorie restriction in 
combination with an exercise programme may be effective as a non-pharmacological 
alternative. Findings from trials in different populations should not be extrapolated to people 
being treated with clozapine. Further trials focusing on clozapine-induced obesity and 
metabolic syndrome are needed. 
Keywords: schizophrenia, clozapine, metabolic syndrome, treatment, meta-analysis  
Abbreviations: BMI: Body mass index; CHAOS: Coronary artery disease, hypertension, 
atherosclerosis, obesity, and stroke; HbA1c: Glycosylated haemoglobin; HDL: High-density 
lipoprotein; Kg: kilogram; LDL: Low-density lipoprotein; RCT: Randomised controlled trial; 
VLDL: Very-low-density lipoprotein. 
 
1 Introduction 
Average life expectancy in people with schizophrenia is about 20 years shorter than the 
general population – this difference is largely attributed to increased mortality from chronic 
physical conditions such as heart disease and diabetes mellitus (Saha et al., 2007). 
Cardiometabolic complications such as weight gain, obesity, metabolic syndrome and 
diabetes mellitus are well recognized side effects of antipsychotics particularly the atypicals 
which are widely used today (De Hert et al., 2011).  
Clozapine is generally regarded as the most efficacious antipsychotic drug (Leucht et al., 
2013), but has been associated with the highest risk for developing obesity and metabolic 
complications compared with other atypical antipsychotics (Allison et al., 1999; Bodén et al., 
2013; Gianfrancesco et al., 2002). It is estimated that the prevalence of metabolic syndrome 
in long-term clozapine users ranges from 28 to 45% (Bai et al., 2011; Bodén et al., 2013).  
Clozapine has affinities for many receptors from multiple neurotransmitter systems. These 
include the dopamine (D1 – D5), serotonin (5-HT1A/1D, 5-HT2A/2C, 5-HT3, 5-HT6, and 5-
HT7), histaminergic (H1 – H3), muscarinic (M1 – 5), adrenergic (α1-2 and β1-3), and 
GABAA receptors (Meltzer, 1994). The difference in the receptor binding profiles of 
different antipsychotics is thought to account for the different weight gain liabilities 
associated with them (Reynolds and Kirk, 2010). The weight gain induced by clozapine is 
highly variable and a twin study by Theisen and colleagues has shown that it is more highly 
correlated in monozygotic twins than in siblings, suggesting that genetic factors may play a 
major role (Theisen et al., 2005). More than 200 genes or markers have been linked to human 
obesity and many of them could be important in clozapine-induced obesity (Basile et al., 
2001).  
 
Formatted: Font: Times New Roman,
12 pt
Formatted: Font: Times New Roman,
12 pt
Formatted: Font: Times New Roman,
12 pt
It has been hypothesised that clozapine causes obesity via its actions on the serotonergic and 
histaminergic systems. Rat studies have shown that 5-HT1A agonists and 5-HT2C/2A 
antagonists cause a marked increase in feeding (Yamada et al., 1996). Clozapine is a potent 
5-HT2C/2A antagonist and a 5-HT1A partial agonist. H1 antagonism is known to be 
associated with increased feeding and weight gain, and antipsychotics with a high propensity 
for weight gain, like clozapine, have strong affinities for the H1 receptor (Wirshing et al., 
1999). Two meta-analyses (De Luca et al., 2007; Sicard et al., 2010) have linked 
polymorphisms in the serotonergic system to clozapine-induced obesity, making it the most 
robust pharmacogenetic mechanism to date that could explain some of the variation in weight 
gain amongst these patients. Despite the evidence, it must be noted that some studies have not 
found such association(Basile et al., 2001; Rietschel et al., 1997; Yevtushenko et al., 2007). 
Results in studies looking at the histaminergic system have shown positive (Vehof et al., 
2011) and negative (Hong et al., 2002) findings. Reviews of the literature (Basile et al., 2001; 
Lett et al., 2012; Müller et al., 2004; Reynolds, 2012) highlight many other targets that have 
been investigated in order to try to explain the variation in weight gain seen in people taking 
clozapine. The results of this research provide clues to the mechanisms behind clozapine-
induced weight gain, but our understanding of this complex phenomenon is still limited and 
further research is warranted. 
 
Clozapine is the gold standard for managing treatment-resistant schizophrenia, which 
comprises approximately 25% of all patients with this condition (Brenner et al., 1990). 
Clozapine is the only antipsychotic approved by the US Food and Drug Administration 
(FDA) for treatment-resistant schizophrenia (Novartis, 2002). Similarly, the UK national 
institute for health and care excellence (NICE) recommends clozapine as the treatment of 
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choice for patients who do not respond to two antipsychotics (NICE, 2014). Clinicians, 
therefore, are faced with a difficult choice between efficacy and long-term cardiometabolic 
complications when choosing clozapine. 
We present a systematic review and meta-analysis of pharmacological and non-
pharmacological treatments for clozapine-induced obesity and metabolic syndrome. Previous 
reviews have considered the effect of weight loss treatments for patients who take 
antipsychotics (Faulkner et al., 2007, 2003; Maayan et al., 2010), but these have included 
studies of various different antipsychotics. Different antipsychotics have very different 
effects on weight gain and metabolic risk (Leucht et al., 2013), so there is a need to focus on 
particular antipsychotics in order to reduce heterogeneity. Given the different mechanisms of 
action of different antipsychotics, and their different metabolic effects, it is reasonable to 
suggest that treatments that may work with one antipsychotic, may not work with another. 
Whitney and colleagues have focused on clozapine (Whitney et al., 2015), but the review 
presented here is distinct in two ways. We report an up-to-date, systematic review and a 
meta-analysis (for metformin) of randomised controlled trials (RCTs) of pharmacological and 
other treatments for clozapine induced obesity and metabolic syndrome. 
2 METHODS 
2.1 Search Strategy 
The PubMed and Embase electronic databases were searched from their inception until the 
30
th
 July, 2015 for all studies (without any filters) involving the management of obesity or 
metabolic syndrome in people taking clozapine using the following search terms: (clozapine 
OR norclozapine OR clozaril OR gen-clozapine OR analeptic OR leponex OR fazaclo OR 
froidir OR denzapine OR zaponex OR klozapol OR clopine) AND (obesity OR (weight AND 
gain) OR (high AND BMI) OR overweight OR obese OR (metabolic AND syndrome) OR 
(syndrome AND X) OR (cardiometabolic AND syndrome) OR (Reaven's AND syndrome) 
OR CHAOS) AND (treatment OR programme OR management OR manage OR managing 
OR therapy OR diet OR regimen OR intervention OR trial OR (randomised AND 
controlled)). An automated search alerted the authors (JZ & CT) by email with any new 
articles published matching the search terms, which was in use up until December 2015. No 
further suitable articles were identified in this way. Reference lists of included studies and 
relevant review articles were hand searched. Two studies were added from this process (Fan 
et al., 2013; Henderson et al., 2011). 
2.2 Study selection 
Double-blind RCTs of interventions to address clozapine-induced obesity or metabolic 
syndrome were selected. Additionally, RCTs where blinding was not possible due to the 
nature of the treatment involved were also included. Studies where some participants were on 
other antipsychotics were included, provided that clozapine was prescribed to the majority 
(>50%) of the study participants and that separate analyses by antipsychotic type were 
conducted. Case reports, case series, and non-randomised trials were excluded. 
2.3 Data extraction 
Two researchers (JZ, CT) carried out the literature search, examined search results, applied 
selection criteria, and selected suitable articles independently by going through all titles and 
abstracts. A list was compiled after discussing potential articles for the review and the full 
text for each article was obtained. Any exclusion after this point was discussed on a case-by-
case basis.  
2.4 Quality assessment of selected studies: 
All the studies included in this review were assessed for quality using the “Consolidated 
Standards of Reporting Trials (CONSORT) statement” checklist (Schulz et al., 2010). There 
are 25 items on the checklist, but some are subdivided into further items, giving a total 
maximum of 37 standards (not all of which are applicable to every study). We calculated a 
quality score for each study, which is the percentage of total applicable standards met by each 
study.  
2.5 Data Synthesis for Meta-Analysis 
Quantitative meta-analysis combined the outcomes of body mass index (BMI), waist 
circumference, serum glucose, high density lipoprotein (HDL) cholesterol, and triglycerides 
from three available trials of metformin as the active treatment (Carrizo et al., 2009; Chen et 
al., 2013; Hebrani et al., 2015). For each outcome, first we calculated mean change-from-
baseline and its standard deviation (SD) for metformin and placebo groups at the end of 
follow-up. Then we calculated mean difference and 95% confidence intervals of mean 
change-from-baseline between groups, which were combined using fixed effect meta-
analysis. Studies were weighted using inverse variance method. Heterogeneity between study 
samples was assessed using Chi-squared test. The I
2
 statistic was calculated to express the 
fraction of variation between studies that was due to heterogeneity (Higgins et al., 2003). 
Because the length of follow-up varied between trials, we used measurements that were taken 
sufficiently close to each other between studies (Carrizo et al at 14 weeks; Chen et al and 
Hebrani et al at 16 weeks). When SD for mean change-from-baseline was not reported we 
used the values for the same outcome measure from other studies in the review. This 
approach is appropriate because the methods for measuring the main outcomes (BMI and 
waist circumference) were similar between studies, and so was the duration of follow-up. 
Meta-analysis was carried out using the software RevMan, version 5.3, freely available from 
the Cochrane collaboration database (Cochrane Informatics & Knowledge Management 
Department, 2015). 
3 RESULTS 
Figure 1 summarises the study selection process for this systematic review. The electronic 
database search yielded 2,370 articles. Twelve other articles were identified from a manual 
search. Screening of titles and abstracts identified 44 potentially suitable articles for the 
review, of which 29 were subsequently discarded after examination of full text versions (see 
online supplementary table for excluded studies).  
[figure 1 here] 
Fifteen studies met the selection criteria. These can be broadly divided into research looking 
at pharmacological, non-pharmacological, and combination of both pharmacological and 
non-pharmacological treatments. The key interventions and findings of these studies are 
summarised in Table 1. 
3.1 Pharmacological Treatments 
3.1.1 Meta-analysis of RCTs of Metformin 
Three RCTs examined metformin as a sole treatment for clozapine-induced obesity and 
metabolic syndrome (Carrizo et al., 2009; Chen et al., 2013; Hebrani et al., 2015). These 
studies carried out a completer analysis of the data. Chen and colleagues did not report any 
participants failing to complete the study (Chen et al., 2013). Carrizo and colleagues reported 
that 7 participants (23%) in the treatment group did not complete the trial (Carrizo et al., 
2009). Hebrani and colleagues had a large drop-out rate with 11 participants (37%) stopping 
the intervention, although 12 participants (40%) in the placebo group also failed to complete 
the study (Hebrani et al., 2015). 
Metformin is an effective and widely used treatment for diabetes mellitus. It is a biguanide 
with antihyperglycaemic effects and is the most studied pharmacological agent for treating 
obesity and metabolic syndrome caused by antipsychotics in general (Fiedorowicz et al., 
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2012).  It lowers both basal and postprandial plasma glucose, but it does not stimulate insulin 
secretion and, hence, does not produce hypoglycaemia.  
3.1.1.1 Effect on BMI and Waist Circumference 
Data on BMI and waist circumference were available from all three RCTs, totalling 71 
participants in the metformin group and 75 participants in the placebo group. Metformin 
treatment was associated significant reductions in BMI and waist circumference (Figure 2, 
panels A & B). At the end of follow-up average BMI was about 1-point lower in the 
metformin group compared with the placebo group; mean difference -0.89 (95% CI, -1.20, -
0.58); P<0.0001. There was no evidence for significant heterogeneity between studies 
(P=0.42; I
2
=0%). Similarly, at the end of follow-up average waist circumference was about 
2cms lower in the metformin group compared with the placebo group; mean difference -1.69 
(95% CI, -2.84, -0.54); P=0.004. Again, no evidence for significant heterogeneity was found 
between studies (P=0.57; I
2
=0%). 
[Figure 2, Panels A-B] 
3.1.1.2  Effect on Blood Glucose and Lipids  
No significant difference between metformin and placebo groups was observed for blood 
glucose, HDL cholesterol and triglyceride levels (Figure 2, panels C-E). 
[Figure 2, Panels C-E] 
3.1.2 Rosiglitazone 
Rosiglitazone is used in monotherapy or combination therapy in patients with diabetes 
mellitus. It works at the transcription factor level in cells that metabolise glucose and fat, with 
the net effect of lowering fasting and post-prandial blood glucose levels and HbA1c levels, 
without causing hypoglycaemia (Yki-Järvinen, 2004). Henderson and colleagues (Henderson 
et al., 2009) looked at the effect of rosiglitazone in a small group of participants (n=18) who 
were treated for 8 weeks. They found no difference in weight, BMI, waist circumference, 
waist-hip ratio, or body fat percentage between groups, but there was some evidence of a 
reduction in low-density lipoprotein (LDL) (effect size = 0.30; p = 0.04) in the treatment 
group. 
3.1.3 Modafinil 
Henderson and colleagues (Henderson et al., 2011) conducted a secondary analysis of a study 
(Freudenreich et al., 2009) looking at the effect of modafinil treatment for 8 weeks on weight 
gain, glucose, lipid metabolism, and diet. They found no significant differences between 
groups in terms of blood pressure, weight, BMI, glucose, insulin resistance, or lipid 
metabolism at the end of follow up. 
3.1.4 Orlistat 
Orlistat, a lipase inhibitor that reduces fat absorption from the intestines (Lucas and Kaplan-
Machlis, 2001), is the only pharmacological treatment available that is not absorbed into the 
central nervous system.  
Joffe and colleagues (Joffe et al., 2008) conducted a RCT looking at the effects of Orlistat on 
weight, fasting glucose, and blood lipids in a group of 63 patients being treated with 
clozapine (n = 50 [79%]) or olanzapine (n = 13 [11%]). The drop-out rates in this study were 
considerable with 7 patients in the treatment group (23%) and 7 in the placebo group (22%) 
failing to complete the study, but the researchers used intention-to-treat analyses to interpret 
the data. After 16 weeks, the only difference they found was a 2.3kg mean weight loss in men 
treated with Orlistat, but not in women. Five people (16.1%) were classified as ‘responders’ 
(>5% weight loss) in the treatment group vs. 2 (6.3%) in the placebo group, but the 
differences were not statistically significant (Fisher exact test, p = 0.26). The amount of 
weight loss seen is similar to that in trials of Orlistat in the non-psychiatric population 
(Padwal et al., 2004). Diarrhoea was the main reason for discontinuation of Orlistat (4 
patients). In a subsequent publication of the same trial (Tchoukhine et al., 2011), they 
analysed the effects of administering Orlistat for a further 16 weeks to participants who 
completed the initial trial, but no additional benefit was found. 
3.1.5 Topiramate 
There is one trial looking at the effects on psychotic symptoms of adding the anticonvulsant 
topiramate to clozapine treatment, where weight loss is mentioned (Afshar et al., 2009). In 
this 8 week, double-blind, placebo controlled, randomised trial (n=32) there was no effect of 
topiramate on BMI. A significantly greater proportion of people in the topiramate group 
reported “weight loss” when compared with those given placebo (37.5% vs. 6.2% [p ≤ 0.05]), 
although the amount of weight loss was not defined. No further information is available from 
the study.We found three trials looking at the effects on psychotic symptoms of adding the 
anticonvulsant topiramate to clozapine treatment (Afshar et al., 2009; Behdani et al., 2011; 
Muscatello et al., 2011). Weight loss was not the primary outcome and was simply 
highlighted as a side effect, hence only limited data is available and meta-analysis was not 
possible. Afshar and colleagues (Afshar et al., 2009) conducted an 8 week, double-blind, 
placebo controlled, randomised trial (n=32) where there was no effect of topiramate 
(300mg/day) on BMI observed. A significantly greater proportion of people in the topiramate 
group reported “weight loss” when compared with those given placebo (37.5% vs. 6.2% [p ≤ 
0.05]), although the amount of weight loss was not defined. No further information is 
available from the study. 
The study of Muscatello and colleagues (Muscatello et al., 2011) mentions a 1kg difference 
in the topiramate group (200mg/day) after 24 weeks of treatment. The weight difference in 
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the placebo group is not reported and the weight loss observed was not found to be 
statistically significant (p = 0.236). 
Finally, Behdani and colleagues (Behdani et al., 2011) conducted a 17 week trial of 
augmenting clozapine with topiramate (200 - 300mg/day). They report that 15% (n= 6) of the 
topiramate group experienced 'weight loss' in comparison with 0% of the placebo group. 
Statistical analyses were not carried out and 'weight loss' is not defined. 
3.1.6 Sibutramine 
Sibutramine was introduced to the US in 1997 as a weight loss agent. It affects serotonin and 
noradrenaline re-uptake, and its hypophagic effect is thought to be mediated by activation of 
the 5-HT2C receptor. It has been withdrawn following evidence that it increases the risk of 
cardiovascular complications (European Medicines Agency, 2010). Following a trial showing 
sibutramine is effective for weight loss in olanzapine treated patients (Henderson et al., 
2005), Henderson and colleagues carried out a 12 week, double-blind, placebo-controlled, 
randomised trial in 21 patients on clozapine (Henderson et al., 2007). They looked at changes 
from baseline in body weight, BMI, waist circumference, glucose, HbA1c, blood lipids, 
Positive and Negative Syndrome Scale (PANSS) scores, blood pressure, and heart rate, but 
found no significant difference on any these measures between groups. 
3.1.7 Phenylpropanolamine 
Phenylpropanolamine is an α1-agonist thought to act as an appetite suppressant by 
augmenting noradrenergic neurotransmission, which used to be sold over-the-counter as a 
treatment for obesity until it was discovered that it increases the risk of haemorrhagic stroke 
in women (Kernan et al., 2000). Borovicka and colleagues (Borovicka et al., 2002) carried 
out the only double-blind, RCT with this agent in 16 people taking clozapine. After 12 weeks, 
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no difference was found between the treatment and the placebo group in terms of weight, 
glucose, HbA1c, or cholesterol levels. 
3.1.8 Aripiprazole 
We identified two studies of Aripiprazole, which were not meta-analysed due to differences 
in methods and duration of follow up. Fleischhacker and colleagues conducted a large, multi-
centre study (n=207), to evaluate the effects of adding aripiprazole to clozapine 
(Fleischhacker et al., 2010). In a last observation carried forward analysis, tThey found that 
aripiprazole reduced weight (mean treatment difference of -2.15 kg), BMI (-0.8 kg/m
2
), LDL 
cholesterol (-10.3 mg/dL), and waist circumference (-2.0 cm) after a treatment period of 16 
weeks. There was no difference in PANSS scores between the treatment group and controls, 
but there were some improvements in the Clinical Global Impression (CGI) scale and in the 
Impressions and Investigator’s Assessment questionnaire in the treatment group. In the 
placebo group 6 (6%) patients failed to complete the study and there were 11 (10%) drop-
outs in those receiving aripiprazole, with 5 (5%) due to adverse events. Some of their results 
are supported by a more recent trial (n = 30) by Fan and colleagues (Fan et al., 2013). They 
looked at the effects of adding 15mg of aripiprazole to patients on clozapine for a period of 8 
weeks. The treatment group showed significant reductions in plasma LDL levels, improved 
glucose effectiveness as measured by the frequently sampled intravenous glucose tolerance 
test, as well as a significant reduction in lean mass (-1.1 ± 1.6kg vs 0.6 ± 1.6kg in placebo) as 
measured by whole-body dual-energy X-ray absorptiometry. There were similar proportions 
of drop-outs in both arms of the study (4 in the placebo (22%) and 4 (20%) in the treatment 
group). It is not specified whether some of their data was used in the analysis or not. 
3.2 Non-Pharmacological treatments 
3.2.1 Calorie restriction and exercise 
Wu and colleagues (Wu et al., 2007) carried out a 6 month RCT of exercise and calorie 
restriction versus treatment as usual in 53 inpatients with schizophrenia taking clozapine. The 
exercise component was designed to fit the hospital environment, and it consisted of three 
days per week of level walking (1.62km or ~40 minutes) together with walking up 231 stairs 
and down 330 stairs for 20 minutes under supervision (exercise energy expenditure per week 
= 600 – 750kcal). Dietary control consisted of 1300 – 1500kcal/day for women and 1600-
1800kcal/day for men. The treatment group had reductions in BMI (- 1.59kg/m2), body 
weight (-4.2kg), hip (-3.3cm) and waist circumference (-3.3cm) after 6 months. They also had 
lower levels of triglycerides, insulin, and cortisol. No group differences were found in 
glucose and cholesterol levels. There were no drop-outs in the treatment group and only 3 
(11%) in the control group. 
3.3 Combination treatments 
3.3.1 Atomoxetine and Weight Watcher’s Programme 
Atomoxetine is a selective norepinephrine reuptake inhibitor used in attention deficit 
hyperactivity disorder, which has been found to have appetite suppressant properties (Spencer 
et al., 1998). It has been postulated to improve cognitive impairments in schizophrenia, 
although scientific evidence for this idea is lacking (Friedman et al., 2008). In a 24 week 
double-blind randomised controlled trial (n=37), Ball and colleagues (Ball et al., 2011) tested 
whether atomoxetine could help achieve weight loss in clozapine (52% of sample) and 
olanzapine treated patients. All participants also undertook a 10 week ‘Weight Watchers’ 
programme (a weight loss programme mainly used in the US, UK, Ireland and Australia) 
which involved diet and exercise. No significant differences were found with regards to 
weight loss, LDL, HDL, triglycerides, very-low-density lipoprotein (VLDL), cognitive 
measures, or symptomatology between groups. Of interest, only 9 (24%) participants (6 on 
placebo and 3 on atomoxetine) who completed the study were adherent to the exercise 
programme, but the amount of weight loss they experienced ranged from <3% to 14% of 
their study baseline weight. 
[Table 1 about here] 
4 Discussion 
Few RCTs looking at treatments for obesity and metabolic syndrome caused by clozapine are 
available. Our results suggest that adjuvant treatment with metformin, aripiprazole or Orlistat 
might be effective pharmacological strategies, albeit with limited clinical impact.  
The evidence on metformin in clozapine-treated patients suggests that its use is likely to have 
a small beneficial effect with regards to body weight, blood lipids, and insulin levels. This is 
thought to be caused by its effects in enhancing the glycaemic control effects of insulin, 
antagonising glucagon, and suppressing gluconeogenesis and glycogenolysis (Wiernsperger 
and Bailey, 1999). Given the short duration of the follow-ups (6 months or less), it is not 
clear as to whether these changes eventually translate to clinically significant effects. One of 
the problems is that benefits seem to stop once metformin is withdrawn (Chen et al., 2013), 
therefore, treatment is likely to be required for life. Adverse effects can also occur and these 
resulted in 6 (20%) of the participants from one study discontinuing the drug (Hebrani et al., 
2015). Metformin is also contraindicated in patients with ketosis-prone diabetes and 
underlying renal, hepatic, or cardiopulmonary disease (Wang et al., 2012).  
Aripiprazole appears to be the only other agent with good evidence against obesity and 
metabolic syndrome induced by clozapine (Fan et al., 2013; Fleischhacker et al., 2010). Its 
effects on weight and cholesterol reduction are thought to be due to its partial agonist effects 
on 5-HT1A receptors and agonist effects on 5-HT2C receptors (Fan et al., 2013). Potential 
candidates need to be warned about the possibility of side effects, such as akathisia, which 
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were observed in some study participants and accounted for nearly half of the drop-outs. It is 
still unclear whether anythe benefits continue after 7 months. 
The results on rosiglitazone (Henderson et al., 2009), topiramate (Afshar et al., 2009), 
modafinil (Henderson et al., 2011), sibutramine (Henderson et al., 2007), 
phenylpropanolamine (Borovicka et al., 2002), and atomoxetine (Ball et al., 2011) are 
disappointing. The effects of Orlistat in body weight appear to be small, limited to men, with 
no further benefit after 16 weeks of use. Some participants also developed diarrhoea, which 
led to discontinuation of the treatment (Joffe et al., 2008). Some studies argue that the lack of 
effect in these agents may be due to a small sample size; however, even if larger samples 
managed to show statistical significance, the magnitude of the effects of these drugs in body 
weight and features of metabolic syndrome would still be small and unlikely to be of much 
clinical significance. 
The effects of calorie restriction and exercise appear to be at least as good, if not better, than 
those of metformin and aripiprazole (Ball et al., 2011; Wu et al., 2007). The study by Wu and 
colleagues produced the best results, but the Chinese participants were all long-term 
inpatients under close scrutiny. They achieved a 90% completion rate in their six-month 
exercise programme without any significant incentives. In the UK, the median length of 
admission is 15 days and only 9.2% of patients are admitted for longer than 90 days 
(Thompson et al., 2004). Achieving that level of commitment in the community would be 
difficult, as can be seen in the US-based study by Ball and colleagues, where only 9 (24%) of 
participants completed the exercise programme, despite provision of free transport to the 
exercise sessions and incentives in the form of tokens that could be used to buy prizes at the 
end of the study. Nevertheless, every participant that finished the programme lost a 
substantial (~3 – 15.9kg) amount of weight (Ball et al., 2011).  
This review shows that treatments that have been successful in ‘atypical’ antipsychotics can 
fail when tested in people taking clozapine. Positive weight loss trials with topiramate in 
people taking atypical antipsychotics (Ko et al., 2005) were not replicated in people treated 
with clozapine (Afshar et al., 2009). A positive trial of sibutramine in people taking 
olanzapine (Henderson et al., 2005) did not translate to clozapine (Henderson et al., 2007).  A 
trial suggestive of modafinil having an impact in cholesterol levels of people treated with 
‘atypical antipsychotics’ (Sudhakar et al., 2008) was not replicated in clozapine-treated 
patients (Henderson et al., 2011). The same applies for medication found to be helpful in the 
general population, as can be seen in the failure of phenylpropanolamine (Borovicka et al., 
2002) and sibutramine (Henderson et al., 2007) in clozapine patients. The lack of an effect of 
these agents on clozapine-treated individuals may be due to different weight gain 
mechanisms given the different receptor affinities of clozapine. 
Limiting the inclusion criteria of this review to randomised controlled trials favoured the 
inclusion of a small number of studies with a low risk of bias over a greater number of studies 
that would have been available, had other types of studies been considered. Given that 
clozapine has been continuously used for over 25 years, it was expected that a larger number 
of randomised controlled trials would have been carried out, but, unfortunately, this was not 
the case. The exclusion of all other types of evidence such as case reports and observational 
studies was done to try to eliminate bias. The limited information available on the topic, 
however, means that useful information may still be obtained from lower levels of evidence 
and the reader should consider looking at those studies that were excluded, as well as looking 
at more general reviews (Faulkner et al., 2007, 2003; Maayan et al., 2010; Whitney et al., 
2015), in order to obtain a broader view of the evidence. 
We conclude that there is evidence for pharmacological and non-pharmacological 
interventions that can help with the metabolic complications of clozapine treatment. The 
benefits of pharmacological interventions have to be weighed against potential side-effects 
and non-pharmacological alternatives can be effective but difficult to implement in 
community settings. The limited impact of all these interventions on clozapine-induced 
metabolic syndrome highlights the need for further research in this field. 
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Figure legend 
 
Figure 1. Study flow diagram for systematic review. PubMed and Embase were searched 
from their inception until 1st December, 2015. The key search terms used included 
'randomised controlled trial', intervention, treatment, BMI, obesity, metabolic syndrome, and 
generic and proprietary terms for clozapine (see Methods). Figure 1. Study flow diagram for 
systematic review. 
 
Figure 2. 
A: Meta-analysis of metformin on BMI. 
B: Meta-analysis of metformin on waist circumference. 
C: Meta-analysis of metformin on fasting blood glucose levels. 
D: Meta-analysis of metformin on HDL cholesterol levels. 
E Meta-analysis of metformin on triglyceride levels. 
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Pharmacological Studies  
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500mg/day for 2 
weeks, then 
1000mg/day 
61 100% Out-patients 
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-1.87kg 
metformin 
vs. +0.16kg 
in placebo. 
N/A 
Increased 
HDL in 
treatment 
group. 
Reduced 
insulin 
levels in 
treatment 
group. 
No 
significan
t changes 
in BPRS 
scores. 
75% 
Chen (2013) China 
Metformin 
1500mg/day 
55 100% 
Out-
patients. 
BMI >24 or 
metabolic 
abnormalitie
s 
24 
weeks 
on 
treatme
nt + 24 
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without. 
-3.2kg at 24 
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(effect lost 
when 
metformin 
stopped). 
-1.2 at 24 
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(effect 
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metformin 
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Reduction 
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metformin 
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fasting 
glucose in 
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No 
significan
t changes 
in 
PANSS 
scores. 
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(2015) 
Iran 
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In-patients 
with a BMI 
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on 
treatme
nt + 4 
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without. 
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e metformin 
vs. +1.0cm 
placebo. 
-1.23 
metformin 
vs. +0.01 
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Reduced 
HDL 
No 
difference
s in 
fasting 
glucose 
levels. 
No 
significan
t changes 
in BPRS 
scores. 
69% 
Henderson 
(2009) 
USA 
Rosiglitazone 
4mg/day 
18 100% 
Out-patients 
Insulin 
resistance or 
impaired 
glucose 
metabolism. 
8 weeks 
No 
significant 
difference in 
weight, 
weight 
circumferenc
e or waist-
hip ratio. 
No 
significant 
difference
s 
Reduced 
small LDL 
particle in 
treatment 
group. 
No 
significant 
changes. 
No 
significan
t changes 
in 
PANSS 
scores. 
53% 
Joffe (2008) Finland Orlistat 360mg/day 63 79% 
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inpatients, 
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outpatients 
receiving 
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olanzapine. 
BMI 28 - 
43. 
16 
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-2.36 kg 
Orlistat vs. 
+0.62kg 
placebo in 
men. 
Women did 
not benefit. 
N/A 
Reduced 
LDL in 
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No 
significant 
changes. 
N/A 69% 
Afshar 
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Iran 
Topiramate 
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25mg increments 
as required every 4 
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Weight loss 
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topiramate 
vs. 6.2% 
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Exact figures 
N/A. 
-0.91 
topiramat
e +0.21 
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Reductio
n in all 3 
categorie
s of the 
PANSS 
in 
topiramat
e group. 
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(2011) 
Iran 
Topiramate (200 – 
300mg/day) 
80 100% In-patients 
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weeks 
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in 15% 
topiramate 
vs. 0% 
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N/A N/A N/A 
No 
significan
t changes 
in 
PANSS 
scores. 
63% 
Muscatello 
(2011) 
Italy 
Topiramate 
(200mg/day)  
60 100% Out-patients 
24 
weeks 
-1.0 kg in 
topiramate 
group 
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reported) 
N/A N/A N/A 
No 
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Bizarre 
behaviou
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reduction 
in 
topiramat
e group 
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Henderson 
(2011) 
USA 
Modafinil 
300mg/day 
35 100% Out-patients 8 weeks 
No 
significant 
differences 
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No 
significant 
difference
s 
No 
significant 
differences 
No 
significant 
difference
s in 
glucose 
levels or 
insulin 
resistance 
No 
significan
t 
differenc
es in 
negative 
symptom
s or 
cognition 
64% 
Henderson 
(2007) 
USA 
Sibutramine 
5-15mg/day 
21 100% 
Out-
patients. 
BMI >30 or 
>27 with 
cardiovascul
ar risk 
factors. 
12 
weeks 
No 
significant 
differences 
in weight or 
waist 
circumferenc
e. 
No 
significant 
difference
s 
No 
significant 
changes. 
No 
significant 
changes. 
No 
significan
t changes 
in 
PANSS 
scores. 
59% 
Borovicka 
(2002) 
USA 
Phenylpropanolam
ine 75mg/day 
16 100% 
Out-
patients. 
Gained 
>10% of 
baseline 
body weight 
12 
weeks 
No 
significant 
differences 
in weight 
N/A 
No 
significant 
changes. 
No 
significant 
changes. 
 
No 
significan
t changes 
in 
PANSS 
scores. 
 
55% 
Fleischhack
er (2010) 
Multi-
centre 
(10 
Europea
n 
countries 
and 
South 
Africa) 
Aripiprazole 
5-15mg/day 
20
7 
100% 
Out-
patients. 
>2.5kg 
weight gain. 
16 
weeks + 
12 
weeks 
open-
label 
extensio
n 
-2.53kg 
aripiprazole 
vs. -0.38kg 
placebo. -
2cm waist 
circumferenc
e 
aripiprazole 
vs. 0cm 
placebo. 
-0.8 
aripiprazo
le vs. 0.0 
placebo. 
 
Reduced 
LDL and 
cholesterol 
in 
treatment 
group. 
No 
difference 
in 
triglyceride
s or HDL 
levels. 
 
No 
significant 
changes. 
No 
significan
t changes 
in 
PANSS 
scores. 
81% 
Fan (2013) USA 
Aripiprazole 
15mg/day 
30 100% Out-patients 8 weeks 
 
No 
difference in 
weight or 
waist 
circumferenc
e. Reduced 
lean mass in 
treatment 
group 
-1.1 ± 1.6kg 
aripiprazole 
vs 0.6 ± 
1.6kg in 
placebo. 
 
No 
significant 
difference
s 
Reduced 
LDL 
plasma 
levels and 
LDL 
particle 
numbers in 
treatment 
group. No 
differences 
in 
cholesterol, 
HDL, or 
triglyceride
s. 
Increased 
insulin-
independe
nt glucose 
clearance 
rate in 
treatment 
group. 
No 
significan
t change 
in 
PANSS 
scores. 
64% 
Non-Pharmacological Studies  
Wu (2007) China 
Calorie restriction 
(1300-
1500kcal/day for 
women and 1600-
1800 kcal/day for 
men) and exercise 
3 times per week 
(600-750kcal of 
exercise per week) 
53 100% 
In-patients. 
BMI > 27. 
6 
months 
-4.2kg 
treatment 
group vs. 
+1kg 
controls. 
-3.3cm hip 
and -3.3cm 
waist 
circumferenc
e treatment 
group vs. 
+0.3cm & 
+0.01cm 
controls. 
-1.59 
treatment 
group vs. 
+0.35 
controls 
Reduced 
triglyceride
s in 
treatment 
group. 
Reduced 
insulin 
levels in 
treatment 
group. 
N/A 58% 
Combination Studies  
Ball (2011) USA 
Atomoxetine 40-
120mg/day + 10 
week Weight 
Watchers 
Programme vs. 
Weight Watchers 
Programme alone. 
37 52% 
Gained 7% 
or more of 
baseline 
body 
weight. 
24 
weeks 
No 
significant 
differences 
in weight. 
 
No 
significant 
changes. 
No 
significant 
changes. 
No 
significan
t changes 
in BPRS 
scores. 
62% 
 
 
Table 1. Randomised controlled trials for obesity and metabolic syndrome in patients treated with clozapine. *The CONSORT score reflects the 
proportion of applicable standards according to the CONSORT checklist (Schulz et al., 2010). Higher scores reflect higher quality of trial reporting. 
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Supplementary Table 
Studies excluded from the systematic review 
Study reference Reason for exclusion 
Henderson et al., 2005b; Kaye, 2003; Lin et al., 
2005; Masopust et al., 2008; Ozenoglu et al., 
2007; Pavlovic, 2005; Pigato et al., 2009; 
Schaefer et al., 2007; Weaver et al., 2010 
Only provided data from case reports 
Aquila and Emanuel, 2000; Cole et al., 2010; 
Hinze-Selch et al., 2000; Kalarchian et al., 2005; 
Kelly et al., 2006; Li et al., 2013; Reinstein et al., 
1999; Schorr et al., 2008 
Not randomised controlled trials 
Daumit et al., 2013; Ghanizadeh et al., 2013; 
Khazaal et al., 2007; Ko et al., 2005; Wang et al., 
2012; Wu et al., 2008 
Patient populations taking multiple 
antipsychotics and the proportion of those 
taking clozapine was less than 50% 
Fernández et al., 2012; Tchoukhine et al., 2011 
Data was obtained from studies already included 
in this review 
Chukhin et al., 2013; Fernández et al., 2010 
Did not provide useful data on weight or 
metabolic abnormalities 
Lu et al., 2004 Not blinded 
Englisch and Zink, 2008 Review article 
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